Mr Sitoh Yih Pin, Independent and Non-Executive Chairman
Mr Sitoh, who is residing in Singapore, was first appointed to the Board as our Non-Executive Chairman and Independent Director of the Company on 29 September 2014, and was last re-elected on 25 April 2018. He is also the Chairman of our Audit Committee and a member of both the Nominating and Remuneration Committees. Mr Sitoh does not hold any shares in the Company or any of its subsidiaries.
Mr Sitoh is a Chartered Accountant. He is the Member of Parliament for Potong Pasir constituency.
Mr Sitoh is also an Independent and Non-Executive Director of Talkmed Group Limited and Yeo Hiap Seng Ltd.
Mr Sitoh was formerly a director of Lian Beng Group Ltd, Allied Technologies Limited and United Food Holdings Limited in the last five years.
Mr Sitoh holds a Bachelor of Accountancy (Honours) degree from the National University of Singapore and is a Fellow member of both the Institute of Singapore Chartered Accountants and Chartered Accountants Australia and New Zealand.
Dr Lee Hung Ming, Executive Vice-Chairman
Dr Lee Hung Ming is our Executive Vice Chairman, an ex-officio member of our Medical Board and Centre Director of Lee Hung Ming Eye Centre since 2007.
Dr Lee is a Senior Consultant Ophthalmologist, currently spearheading Lee Hung Ming Eye Centre (formerly known as Parkway Eye Centre) at Gleneagles Hospital. He is a renowned LASIK and cataract specialist and is considered a key opinion leader in his fields of subspecialty, namely cornea, refractive surgery, external eye disease, cataract and implant surgery. Dr Lee held the position of Senior Consultant for Cataract, Cornea & Refractive Surgery Service at The Eye Institute, National Group, Singapore, which he joined in 2003. Dr Lee currently also sits on the Asia Refractive Council of Bausch & Lomb.
Between 2002 and 2007, he was also Clinical Director of the LASIK Centre of the National University Hospital.
From 2000 to 2007, Dr Lee was appointed as Head & Senior Consultant in Tan Tock Seng Hospital, Refractive Surgery.
He completed his residency in ophthalmology at Tan Tock Seng Hospital and the Singapore National Eye Centre, and completed a clinical fellowship in Cornea, External Eye Disease and Refractive Surgery at the University of Toronto.
He has sat on board of various professional associations, such as the College of Ophthalmologists, Surgeons and Singapore Society of Ophthalmologist and Bausch & Lomb’s Asia Refractive Council. He has also been the examiner for the specialist post-graduate examination by the National University of Singapore and the Royal College of Surgeons, Edinburgh (UK), University Sains Malaysia and University Malaya. He was also visiting professor at University Sains Malaysia. Dr Lee has also presented widely at regional and international ophthalmology conferences.
Dr Lee has received various awards, including the A.C.E. Award (APSCRS Certified Educator Award) in 2003 for excellence in training and education of eye surgeons in the Asia Pacific region by the Asia Pacific Society of Cataract and Refractive Surgery, the International Gold Medal in 2011 by the Indian Intraocular Implant and Refractive Society for outstanding contribution in the field of ophthalmology, as well as the University of Toronto John Gaby Research Prize. Dr Lee is a licensed medical practitioner in Singapore, the United Kingdom and Canada. He is a member of the Chapter of Ophthalmologist at the Academy of Medicine, Singapore.
Dr Lee graduated from the National University of Singapore with a Bachelor of Medicine and Bachelor of Surgery in 1989 and subsequently obtained his Master of Medicine in Ophthalmology from the Graduate School of Medical Studies, National University of Singapore, FRCS from the Royal College of Edinburgh Scotland and FAMS (Ophth) from the Academy of Medicine, Singapore.
Mr Lim Wee Hann, Indendent and Non-Executive Director
Mr Lim Wee Hann is our Independent Director and was appointed to our Board on 29 September 2014.
Mr Lim currently practises as an advocate and solicitor and is an Equity Partner, Co-Head of the Mergers & Acquisitions Practice Group at Rajah & Tann Singapore LLP and Executive Committee Member of Rajah & Tann LCT Lawyers. He is also called to the Malaysian Bar and is an Equity Partner of Messrs Christopher & Lee Ong, the Malaysian member firm of Rajah & Tann Asia.
He has over 23 years of experience in the legal sector and specialises in cross-border investments, private mergers and acquisitions and other corporate transactions, labour and employment law, and also has significant biotechnology, health and pharmaceutical practice background. Mr Lim has been a recommended lawyer in the Practical Law Company’s Which Lawyer? (2006 to 2013) for his work in the life sciences industry and has been listed by The International Who’s Who of Life Sciences Lawyers (2008 to 2014) as one of the world’s leading practitioners in the field of life sciences. He currently also sits on the board of A. Menarini Asia-Pacific Holdings Pte. Ltd., part of Menarini group, the largest Italian multinational biopharmaceutical company.
Between January and July 2013, Mr Lim was also an Equity Partner at Messrs Kamilah & Chong, Malaysia.
Between 2000 and 2007, Mr Lim was a Director of Drew & Napier LLC. Between 1996 and 2000, Mr Lim was a partner of Drew & Napier, and between 1992 and 1995, he was a legal associate at Drew & Napier. Between 1991 and 1992, he was with Colin Ng & Partners as a legal associate.
Mr Lim is a member of the Law Society of Singapore, the Singapore Academy of Law and the Bar Council of Malaysia.
Mr Lim graduated from the National University of Singapore with a Bachelor of Law (Honours) in 1990.
Mr Chen Bang, Non-Executive and Non-Independent Director
Mr Chen Bang was appointed to the Board of as a Non-Executiveand Non-Independent Director on 27 December 2019.
Mr Chen is seeking re-election pursuant to Article 118 of the Company’s constitution and the additional information required under Appendix 7F – Announcement of Appointment of the Catalist Rules are set out in this profile. The re-election of Mr Chen as Non-Executive and Non-Independent Director was recommended by the Nominating Committee and approved
by the Board, after taking into consideration his qualifications, expertise and past experiences.
Mr Chen is a director of a substantial shareholder of the Company, Aier Eye International (Singapore) Pte. Ltd..
In relation to Mr Chen’s working experience and occupation, Mr Chen is the Chairman and controlling shareholder of Aier Eye Hospital Group Co., Ltd. (“Aier”) since 2003 whose main business is similar to the Group. As at the date of this Annual Report, Aier Group has no business in Southeast Asia, other than those carried out by our Group.
His country of principal residence is the People’s Republic of China.
Mr Chen has over 20 years of experience in the eye care sector. He co-founded Aier in 2003, and was instrumental in leading it to become the largest eye care group in the world by number of hospitals and by market capitalisation. Aier is listed on the Shenzhen Stock Exchange.
Mr Chen Bang is also the Chairman of Clínica Baviera, S.A. which is a Spain-based company listed on the Madrid Stock Exchange engaged in the healthcare sector and focuses on providing services within the field of ophthalmic medicine.
He has been widely recognised for his entrepreneurship and was awarded “Most Respected Chairman of Chinese Listed Company” in 2011 and 2012 and named “EY Entrepreneur of The Year” in 2014 and “China Most Influential Listed Company Leader” in both 2014 and 2015.
For his philanthropic work, Mr Chen was given the “Hunan Charity Award” in 2015. He graduated from Hunan University with an MBA in 2007.
Mr Li Li, Non-Executive and Non-Independent Director
Mr Li Li was appointed to the Board as our Non-Executive and Non-Independent Director on 25 March 2020.
Mr Li is seeking re-election pursuant to Article 118 of the Company’s Constitution and the additional information required under Appendix 7F of the Catalist Rules are set out in this profile. The re-election of Mr Li as Non-Executive and Non-Independent Director was recommended by the Nominating Committee and approved by the Board, after taking into
consideration his qualifications, expertise and past experiences.
Mr Li was nominated to be appointed as a Director by a substantial shareholder of the Company, Aier Eye International (Singapore) Pte. Ltd..
In relation to Mr Li’s working experience and occupation, Mr Li is the Vice-Chairman of Aier Eye Hospital Group Co., Ltd. (“Aier”) since 2003 whose main business is similar to the Company. As at the date of this Annual Report, Aier Group has no business in Southeast Asia, other than those carried out by our Group.
His country of principal residence is the People’s Republic of China.
Mr Li was one of the co-founders of Aier in 2003 and played a key role in spearheading Aier into the largest eye care group in the world by number of hospitals and market capitalisation. With over 20 years of experience in the eye care sector, he is the Vice-Chairman and CEO of Aier and sits on the Board of Clinica Baviera, S.A., which is a Spain-based company listed on the Madrid Stock Exchange engaged in the healthcare sector and focuses on providing services within the field of ophthalmic medicine.
Mr Li was recognised for his outstanding entrepreneurship and leadership in 2018 with the “Outstanding Entrepreneur Award” by Changsha High-Tech Zone. He is also a strong advocate of education, having established AIER School of Ophthalmology, AIER School of Optometry, AIER Ophthalmology Institute, AIER Institute of Optometry and others, since 2015. He is also the dean of AIER Management School, honorary lifetime supervisor of Eye Care Foundation, Vice Chairman of Chinese nongovernment Medical Institution Association and group leader of Ophthalmic Management.
Ms Zhang Yongmei, Non-Executive and Non-Independent Director
Ms Zhang Yongmei was appointed to Board as a Non-Executive and Non-Independent Director on 27 December 2019.
Ms Zhang is seeking re-election pursuant to Article 118 of the Company’s constitution and the additional information required under Appendix 7F – Announcement of Appointment of the Catalist Rules are set out in this profile. The re-election of Ms Zhang as Non-Executive and Non-Independent Director, and member of the Audit Committee, Nominating Committee
and Remuneration Committee, was recommended by the Nominating Committee and approved by the Board, after taking into consideration her qualifications, expertise and past experiences.
Ms Zhang is a director of a substantial shareholder of the Company, Aier Eye International (Singapore) Pte. Ltd..
Ms Zhang is a member of the management of Aier Eye Hospital Group Co., Ltd. (“Aier”) and its subsidiaries (collectively, the “Aier Group”) whose main business is similar to the Company. As at the date of this Annual Report, Aier Group has no business in Southeast Asia, other than those carried out by our Group.
Her country of principal residence is the People’s Republic of China. Ms Zhang is a non-practising member of The Chinese Institute of Certified Public Accountants (CICPA) and has extensive experience in corporate finance and M&A. She joined Aier Eye Hospital Group Co., Ltd. in 2014 as Global Strategy and Business Development Director. From 2012 to 2014, she
was Corporate Development Senior Manager in Best Buy Corporation and in charge of the development strategy and execution of projects for new ventures. From 2011 to 2012, she was Strategy & Business Development (M&A) Senior Manager and led the M&A team covering the healthcare value chain. From 2007 to 2011, she was Transaction Services & Global Health Senior Manager in PricewaterhouseCoopers and carried out financial due diligence in M&A projects and healthcare strategy advisory.
Ms Zhang is also a director of Clínica Baviera, S.A., which is a Spain-based company listed on the Madrid Stock Exchange engaged in the healthcare sector and focuses on providing services within the field of ophthalmic medicine.
She graduated from Tongji University with a Bachelor of Science degree in 2002 and Fudan University with an MBA in 2013.